Incontinence in late-onset Pompe disease: an underdiagnosed treatable condition.

نویسندگان

  • Gauthier Remiche
  • Anne-Geneviève Herbaut
  • Dario Ronchi
  • Costanza Lamperti
  • Francesca Magri
  • Maurizio Moggio
  • Nereo Bresolin
  • Giacomo P Comi
چکیده

From our previously described LOPD cohort [20] , we studied only patients being clinically revisited (n = 20). Inclusion criteria for LOPD diagnosis were positivity for at least 2 of the following criteria: low GAA enzyme assay ( ! 30%) [8] , vacuolar myopathy and/or increased acid-phosphatase and/or periodic acid-Schiff stain and double GAA gene mutation. We systematically asked the patients if they had urinary or fecal incontinence, diarrhea or constipation. Main causes of incontinence such as central nervous system disease, peripheral nerve disease, dysautonomia or pelvic surgery were systematically and reasonably excluded by standardized detailed anamnesis and clinical examination in each patient. Women were asked to disclose their maternity status, and in men prostatism was assessed. The main Dear Sir, Late-onset Pompe disease (LOPD) is an autosomal recessive multisystemic lysosomal storage disease caused by acid alpha-glucosidase (GAA) deficiency [1–5] . Incidence of Pompe disease varies between 1: 40,000 and 1: 156,000 [6–8] . Except in myotonic dystrophy type 1 (DM1) [9–12] , incontinence is rarely reported in myopathies [13–15] . Nevertheless, it is a disabling condition in social as well as in professional life [16] . LOPD patients generally have nonhomogeneous muscle involvement (e.g. predominance of atrophy on the posterior compartment of the femoral muscles) [17] . To the best of our knowledge, incontinence has been reported in only 4 LOPD patients (2 urinary and 2 fecal) [18, 19] . Bernstein et al. [19] reported the case of an LOPD incontinent patient with subjective improvement after 3 months of enzyme replacement therapy (ERT). Pathophysiologic hypotheses for incontinence in myopathies include striated and smooth pelvic floor muscle as well as lower motor neuron or autonomic involvement [9–11, 14] . We aimed to assess the prevalence of fecal and urinary incontinence in LOPD and to determine if incontinent patients presented a more severe phenotype. We foReceived: January 2, 2012 Accepted: April 2, 2012 Published online: June 29, 2012

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Late-onset Pompe Disease with Elevated Liver Transaminases: A Case Report

Pompe disease or type II glycogen storage disease is a rare autosomal hereditary disease. The prevalence of the disease is about 1 in 40,000 to 1 in 300,000 population. It usually occurs as a result of glycogen accretion following acid maltase deficiency. The current treatment is enzyme replacement therapy, which may slow down the disease progression. Sometimes, the clinical presentation can be...

متن کامل

Consensus treatment recommendations for late-onset Pompe disease.

INTRODUCTION Pompe disease is a rare, autosomal recessive disorder caused by deficiency of the glycogen-degrading lysosomal enzyme acid alpha-glucosidase. Late-onset Pompe disease is a multisystem condition, with a heterogeneous clinical presentation that mimics other neuromuscular disorders. METHODS Objective is to propose consensus-based treatment and management recommendations for late-ons...

متن کامل

Expanding the phenotype of late-onset Pompe disease: tongue weakness: a new clinical observation.

INTRODUCTION Following the clinical observation of lingual weakness in 2 patients with late-onset Pompe disease (LOPD), tongue strength was assessed in 19 consecutive patients to determine the frequency and severity of this neurological sign. METHODS Lingual strength was assessed using manual muscle testing; if weakness was present, severity was established as mild, moderate, or severe. RES...

متن کامل

Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group

BACKGROUND Pompe disease is a rare autosomal recessive disorder caused by a deficiency of the lysosomal enzyme alpha-glucosidase responsible for degrading glycogen. Late-onset Pompe disease has a complex multisystem phenotype characterized by a range of symptoms. METHODS An expert panel from the Middle East and North Africa (MENA) region met to create consensus-based guidelines for the diagno...

متن کامل

The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?

Pompe disease/glycogen storage disease type II, is a rare, lysosomal storage disorder associated with progressive proximal myopathy, causing a gradual loss of muscular function and respiratory insufficiency. Studies of patients with late-onset Pompe disease have used endpoints such as the 6-minute walking test (6MWT) and forced vital capacity (FVC) to assess muscular and respiratory function du...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • European neurology

دوره 68 2  شماره 

صفحات  -

تاریخ انتشار 2012